carmustine has been researched along with Leukemia in 45 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 9.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 5.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 5.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| "At this time, methotrexate and CNS radiotherapy used together offer the best chance for prolonged remissions in children who develop overt CNS leukemia." | 4.76 | Treatment of overt CNS leukemia. ( Filler, J; Humphrey, GB; Krous, HF; Maxwell, JD; VanHoutte, JJ, 1979) |
| "Based on experience with comprehensive patient involvement, we present data from implementation of portable, programmable infusion pumps (PPP) for home-based chemotherapy administration in patients with acute leukaemia and in lymphoma patients receiving (carmustine, etoposide, cytarabine, melphalan) BEAM regimen." | 3.88 | Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma. ( Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC, 2018) |
| "Acute leukemia has developed in 14 patients." | 2.65 | The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. ( Bailey, AJ; Bergsagel, DE; Langley, GR; MacDonald, RN; Miller, AB; White, DF, 1979) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| " Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations." | 2.37 | Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 1.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Fifteen patients had chronic myelogenous leukemia in chronic phase or acute leukemia in first remission (standard risk) and twenty-eight patients with more advanced disease (high risk)." | 1.28 | Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. ( Andersson, BS; Brunner, LJ; Huan, SD; LeMaistre, CF; Spencer, V; Spinolo, JA; Spitzer, G; Wallerstein, RO; Woo, SY; Yau, JC, 1992) |
| " Estrogen replacement should be initiated after transplantation in women to prevent adverse effects of long-term ovarian failure." | 1.28 | Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. ( Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (64.44) | 18.7374 |
| 1990's | 10 (22.22) | 18.2507 |
| 2000's | 4 (8.89) | 29.6817 |
| 2010's | 2 (4.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fridthjof, KS | 1 |
| Kampmann, P | 1 |
| Dünweber, A | 1 |
| Gørløv, JS | 1 |
| Nexø, C | 1 |
| Friis, LS | 1 |
| Nørskov, KH | 1 |
| Welinder, PC | 1 |
| Moser, C | 1 |
| Kjeldsen, L | 1 |
| Møller, T | 1 |
| Stankiewicz-Kranc, A | 1 |
| Bielawska, A | 1 |
| Bielawski, K | 1 |
| Skrzydlewska, E | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Yamauchi, T | 1 |
| Kawai, Y | 1 |
| Ueda, T | 1 |
| Santos-Silva, MC | 1 |
| Freitas, MS | 1 |
| Assreuy, J | 1 |
| Beschorner, WE | 1 |
| Pino, J | 1 |
| Boitnott, JK | 1 |
| Tutschka, PJ | 1 |
| Santos, GW | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Preussmann, R | 1 |
| Kanter, PM | 1 |
| Schwartz, HS | 1 |
| West, CR | 1 |
| Sklar, CA | 1 |
| Kim, TH | 1 |
| Ramsay, NK | 1 |
| Passe, S | 1 |
| Miké, V | 1 |
| Mertelsmann, R | 1 |
| Gee, TS | 2 |
| Clarkson, BD | 2 |
| Gomez, GA | 1 |
| Aggarwal, KK | 1 |
| Han, T | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Goldstone, AH | 1 |
| Newland, AC | 1 |
| Ikuta, K | 1 |
| Fujioka, K | 1 |
| Sumita, H | 1 |
| Takahashi, H | 1 |
| Sekiguchi, H | 1 |
| Kai, S | 1 |
| Kajigaya, Y | 1 |
| Funabiki, T | 1 |
| Sakai, H | 1 |
| Matsuyama, S | 1 |
| Lyytikäinen, O | 1 |
| Elonen, E | 1 |
| Lautenschlager, I | 1 |
| Jokipii, A | 1 |
| Tiittanen, L | 1 |
| Ruutu, P | 1 |
| Rosenfeld, CS | 1 |
| Bolwell, B | 1 |
| LeFever, A | 1 |
| Taylor, R | 1 |
| List, A | 1 |
| Fay, J | 1 |
| Collins, R | 1 |
| Andrews, F | 1 |
| Pallansch, P | 1 |
| Schuster, MW | 1 |
| Resta, D | 1 |
| Levitt, D | 1 |
| Nemunaitis, J | 1 |
| Ager, S | 1 |
| Mahendra, P | 1 |
| Richards, EM | 1 |
| Bass, G | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Laughlin, MJ | 1 |
| McGaughey, DS | 1 |
| Crews, JR | 1 |
| Chao, NJ | 1 |
| Rizzieri, D | 1 |
| Ross, M | 1 |
| Gockerman, J | 1 |
| Cirrincione, C | 1 |
| Berry, D | 1 |
| Mills, L | 1 |
| Defusco, P | 1 |
| LeGrand, S | 1 |
| Peters, WP | 1 |
| Vredenburgh, JJ | 1 |
| Yen, CC | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fang, FS | 1 |
| Wang, WS | 1 |
| Tung, SL | 1 |
| Tzeng, CH | 1 |
| Chen, PM | 1 |
| Barta, A | 1 |
| Batai, A | 1 |
| Torbagyi, E | 1 |
| Sipos, A | 1 |
| Lengyel, L | 1 |
| Petranyi, GG | 1 |
| Paloczi, K | 1 |
| Kelemen, E | 1 |
| Wheeler, C | 1 |
| Khurshid, A | 1 |
| Ibrahim, J | 1 |
| Elias, A | 1 |
| Mauch, P | 1 |
| Ault, K | 1 |
| Antin, J | 1 |
| Nissen, NI | 1 |
| Pajak, TF | 1 |
| Glidewell, O | 1 |
| Pedersen-Bjergaard, J | 1 |
| Stutzman, L | 1 |
| Falkson, G | 1 |
| Cuttner, J | 1 |
| Blom, J | 1 |
| Leone, L | 1 |
| Sawitsky, A | 1 |
| Coleman, M | 1 |
| Haurani, F | 1 |
| Spurr, CL | 1 |
| Harley, JB | 1 |
| Seligman, B | 1 |
| Cornell, C | 1 |
| Henry, P | 1 |
| Senn, HJ | 1 |
| Brunner, K | 1 |
| Martz, G | 1 |
| Maurice, P | 1 |
| Bank, A | 1 |
| Shapiro, L | 1 |
| James, GW | 1 |
| Holland, JF | 1 |
| Humphrey, GB | 1 |
| Krous, HF | 1 |
| Filler, J | 1 |
| Maxwell, JD | 1 |
| VanHoutte, JJ | 1 |
| Bergsagel, DE | 1 |
| Bailey, AJ | 1 |
| Langley, GR | 1 |
| MacDonald, RN | 1 |
| White, DF | 1 |
| Miller, AB | 1 |
| Schreml, W | 1 |
| Bargon, G | 1 |
| Anger, B | 1 |
| Kubanek, B | 1 |
| Heimpel, H | 1 |
| Nicolin, A | 1 |
| Cavalli, M | 1 |
| Missiroli, A | 1 |
| Goldin, A | 2 |
| Cardinali, G | 1 |
| Catalano, G | 1 |
| Lee, SM | 1 |
| Crowther, D | 1 |
| Scarffe, JH | 1 |
| Dougal, M | 1 |
| Elder, RH | 1 |
| Rafferty, JA | 1 |
| Margison, GP | 1 |
| Yau, JC | 1 |
| LeMaistre, CF | 1 |
| Andersson, BS | 1 |
| Huan, SD | 1 |
| Wallerstein, RO | 1 |
| Woo, SY | 1 |
| Spitzer, G | 4 |
| Spinolo, JA | 1 |
| Spencer, V | 1 |
| Brunner, LJ | 1 |
| Kolb, HJ | 1 |
| Bender-Götze, C | 1 |
| Haas, RJ | 1 |
| Holler, E | 1 |
| Thierfelder, S | 1 |
| Wilmanns, W | 1 |
| Keilholz, U | 1 |
| Körbling, M | 1 |
| Fehrentz, D | 1 |
| Bauer, H | 1 |
| Hunstein, W | 1 |
| Brent, TP | 1 |
| Lestrud, SO | 1 |
| Smith, DG | 1 |
| Remack, JS | 1 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Tafuri, A | 1 |
| Meloni, G | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Dicke, KA | 2 |
| Jagannath, S | 3 |
| Walters, RS | 1 |
| Horwitz, LJ | 2 |
| Appelbaum, FR | 1 |
| Buckner, CD | 1 |
| Vellekoop, L | 2 |
| Zander, AR | 2 |
| Keating, M | 2 |
| McCredie, KB | 1 |
| Culbert, S | 1 |
| Larry, N | 1 |
| Cockerill, K | 1 |
| Hester, J | 1 |
| Horwitz, L | 1 |
| Donadio, D | 1 |
| Navarro, M | 1 |
| Izarn, P | 1 |
| Greene, MH | 1 |
| Boice, JD | 1 |
| Strike, TA | 1 |
| Carbone, PP | 1 |
| Frei, E | 1 |
| Schabel, FM | 1 |
| Dowling, MD | 1 |
| Haghbin, M | 1 |
| Cunningham, B | 1 |
| Tan, CT | 1 |
| Burchenal, JH | 1 |
| Pruzanski, W | 1 |
| Saito, S | 1 |
| Medoff, G | 1 |
| Schlessinger, D | 1 |
| Kobayashi, GS | 1 |
| Shapiro, WR | 1 |
| Chernik, NL | 1 |
| Posner, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for carmustine and Leukemia
| Article | Year |
|---|---|
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Treatment of overt CNS leukemia.
Topics: Adrenal Cortex Hormones; Aminopterin; Antineoplastic Agents; Asparaginase; Blood-Brain Barrier; Carm | 1979 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
9 trials available for carmustine and Leukemia
| Article | Year |
|---|---|
Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug | 1982 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1993 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi | 1996 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B.
Topics: Adult; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Femal | 1979 |
The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combinati | 1979 |
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamid | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Carmustine as a cause of acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Humans; Leukemia; Male; | 1985 |
33 other studies available for carmustine and Leukemia
| Article | Year |
|---|---|
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmust | 2018 |
Proline analogue of nitrosourea as a new cytotoxic prodrug.
Topics: Antioxidants; Carmustine; Cell Line, Tumor; Cytotoxins; Fibroblasts; Humans; Leukemia; Nitrosourea C | 2009 |
Alkylator-induced DNA excision repair in human leukemia CCRF-CEM cells in vitro, measured using the single-cell gel electrophoresis (comet) assay.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Comet Assay; DNA Repair; Humans; Kinetics | 2002 |
Involvement of NF-kappaB and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells.
Topics: Buthionine Sulfoximine; Carmustine; Cell Line, Tumor; Glutathione; Humans; Leukemia; NF-kappa B; Nit | 2006 |
Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Carmustine; Cytomegalovirus Infections; Gra | 1980 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Functional and chemical markers of PCNU activity.
Topics: Animals; Antineoplastic Agents; Carmustine; DNA; Humans; Leukemia; Mice; Nitrosourea Compounds; Phen | 1983 |
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Carmustine; Child; Child, Preschoo | 1982 |
Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined | 1982 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1996 |
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 1998 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hemat | 1998 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2001 |
[Progressive pulmonary fibrosis during combination chemotherapy with BCNU (author's transl)].
Topics: Acute Disease; Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; | 1978 |
Immunogenicity induced in vivo by DIC in relatively non-immunogenic leukemias.
Topics: Animals; Antibody Formation; Carmustine; Dacarbazine; Leukemia; Leukemia, Experimental; Male; Mice; | 1977 |
[Models of polychemotherapy in acute leukemias].
Topics: Acute Disease; Antineoplastic Agents; Asparaginase; Carmustine; Cyclophosphamide; Cytarabine; Dacarb | 1975 |
Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation.
Topics: Acrolein; Adenosine Triphosphatases; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Cyc | 1992 |
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy | 1992 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1989 |
Formation of DNA interstrand cross-links by the novel chloroethylating agent 2-chloroethyl(methylsulfonyl)methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts.
Topics: Carmustine; Cross-Linking Reagents; DNA Damage; DNA Repair; Humans; In Vitro Techniques; Leukemia; L | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1987 |
The role of autologous bone marrow transplantation in acute leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Evaluation Studies as Topi | 1987 |
High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1986 |
High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmusti | 1987 |
[Neuromeningeal localizations in acute leukemia and non-Hodgkin's lymphoma. Protocol combining BCNU-cytosine arabinoside].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabi | 1987 |
International Symposium on Hodgkin's Disease. Session 4. Small group workshops. Report on workshop: Chemotherapy.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Doxorubicin; Drug Therapy, Combination; Hodgkin Diseas | 1973 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Comparative results obtained in the treatment of acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination | 1973 |
Influence of chemotherapeutic agents on the antibacterial activity of normal and leukemic sera.
Topics: Antineoplastic Agents; Blood Bactericidal Activity; Carmustine; Cell Membrane; Complement System Pro | 1974 |
Brief communication: polyene potentiation of antitumor agents.
Topics: Amphotericin B; Animals; Carmustine; Cell Division; Cell Survival; Clone Cells; Drug Synergism; L Ce | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |